Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - efmoroctocog alfa, quantity: 1000 iu - drug delivery system - excipient ingredients: - eloctate is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia a (congenital factor viii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis). eloctate does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - efmoroctocog alfa, quantity: 2000 iu - drug delivery system - excipient ingredients: - eloctate is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia a (congenital factor viii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis). eloctate does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - efmoroctocog alfa, quantity: 250 iu - drug delivery system - excipient ingredients: - eloctate is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia a (congenital factor viii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis). eloctate does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - efmoroctocog alfa, quantity: 3000 iu - drug delivery system - excipient ingredients: - eloctate is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia a (congenital factor viii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis). eloctate does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - efmoroctocog alfa, quantity: 500 iu - drug delivery system - excipient ingredients: - eloctate is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia a (congenital factor viii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis). eloctate does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - moroctocog alfa, quantity: 2000 iu - diluent, not applicable - excipient ingredients: sodium chloride; water for injections - the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - moroctocog alfa, quantity: 1000 iu - injection, powder for - excipient ingredients: sodium chloride; histidine; hydrochloric acid; sucrose; polysorbate 80; calcium chloride dihydrate - the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - moroctocog alfa, quantity: 500 iu - injection, powder for - excipient ingredients: histidine; calcium chloride dihydrate; polysorbate 80; sucrose; sodium chloride; hydrochloric acid - the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - moroctocog alfa, quantity: 250 iu - injection, powder for - excipient ingredients: polysorbate 80; sodium chloride; hydrochloric acid; histidine; sucrose; calcium chloride dihydrate - the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - moroctocog alfa, quantity: 3000 iu - injection, solution - excipient ingredients: sodium chloride; water for injections - xyntha is indicated for the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.